Osteoanabolic therapy for reduction of refracture risk after vertebral augmentation procedures? Response to Massarotti et al
Crossref DOI link: https://doi.org/10.1007/s00198-016-3657-9
Published Online: 2016-06-10
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Beall, D.
Krohn, K.
Funding for this research was provided by:
Eli Lilly and Company
License valid from 2016-06-10